Pine Valley Investments Ltd Liability Co Purchases 204 Shares of Amgen Inc. (NASDAQ:AMGN)

Pine Valley Investments Ltd Liability Co increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 4.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,913 shares of the medical research company’s stock after buying an additional 204 shares during the quarter. Pine Valley Investments Ltd Liability Co’s holdings in Amgen were worth $1,280,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. BankPlus Trust Department acquired a new stake in Amgen during the fourth quarter worth approximately $2,081,000. Rothschild Investment LLC grew its position in Amgen by 2.8% during the fourth quarter. Rothschild Investment LLC now owns 60,259 shares of the medical research company’s stock worth $15,706,000 after buying an additional 1,642 shares in the last quarter. IFP Advisors Inc grew its position in Amgen by 6.2% during the fourth quarter. IFP Advisors Inc now owns 6,102 shares of the medical research company’s stock worth $1,591,000 after buying an additional 357 shares in the last quarter. Mainstay Capital Management LLC ADV grew its position in Amgen by 3.6% during the fourth quarter. Mainstay Capital Management LLC ADV now owns 4,980 shares of the medical research company’s stock worth $1,298,000 after buying an additional 171 shares in the last quarter. Finally, B&D White Capital Company LLC acquired a new stake in Amgen during the fourth quarter worth approximately $1,173,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other news, EVP David M. Reese sold 8,711 shares of Amgen stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total value of $2,554,239.42. Following the completion of the transaction, the executive vice president now directly owns 62,147 shares of the company’s stock, valued at approximately $18,222,743.34. This trade represents a 12.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,341 shares of company stock valued at $20,644,335. Corporate insiders own 0.69% of the company’s stock.

Amgen Stock Up 1.9 %

Shares of NASDAQ:AMGN opened at $315.63 on Wednesday. The firm has a market cap of $169.56 billion, a P/E ratio of 41.81, a P/E/G ratio of 2.63 and a beta of 0.56. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The business has a fifty day simple moving average of $278.13 and a 200 day simple moving average of $300.16.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.02%. Amgen’s dividend payout ratio (DPR) is 126.09%.

Analysts Set New Price Targets

AMGN has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft reduced their price target on Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Citigroup reaffirmed a “neutral” rating on shares of Amgen in a report on Wednesday, February 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Redburn Partners reduced their target price on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Finally, William Blair reaffirmed an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus price target of $314.09.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.